1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025

Summary

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease (CVD), and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial.

The clinical diagnostic criteria for dyslipidemia and serum lipid abnormalities vary across countries and depend on the disease treatment and management guidelines that are followed in each country. Guidelines for the detection, evaluation, treatment, and management of dyslipidemia, as well as the prevention of associated CVD, are updated periodically, which has led to further differences over the past several decades in how the prevalence of dyslipidemia is assessed in different studies. For this analysis, GlobalData epidemiologists estimated the total prevalent cases of serum lipid abnormalities according to country-specific cut-offs.

In 2015, there were 580,825,262 total prevalent cases of dyslipidemia in the 8MM. This is forecast to grow to 680,288,645 by 2025, at an Annual Growth Rate (AGR) of 1.71%. Urban China made up the majority of the total prevalent cases in the 8MM throughout the forecast period, and will also experience the highest growth from 274,741,284 total prevalent cases of dyslipidemia in 2015 to 348,184,445 cases by 2025, at an AGR of 2.67%. The US is forecast to grow at an AGR of 1.34%, from 133,104,335 total prevalent cases of dyslipidemia in 2015 to 150,918,348 cases by 2025. In the 8MM, there were 317,925,626 diagnosed prevalent cases of dyslipidemia, which is forecast to grow to 370,440,489 by 2025.

GlobalData epidemiologists used comprehensive, country-specific data from population-based national health surveys, such as the NHANES in the US and the CHNS in urban China. Additionally, data from peer-reviewed journal articles were utilized to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, as well as other therapeutically significant patient populations including the diagnosed prevalent cases of dyslipidemia and the total prevalent cases of FH.

Scope

- The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of dyslipidemia-which are defined as elevated low-density lipoprotein cholesterol (LDL-C), high triglycerides (TG), or low levels of high-density lipoprotein cholesterol (HDL-C)-as well as the total prevalent cases of increased LDL-C, and very high TG, segmented by sex and age. Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) and very high TG in these markets.
- The dyslipidemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Dyslipidemia EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
- Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.
- Understand the distribution of types of dyslipidemia and FH in these markets.

Table Of Contents

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Epidemiology 7
2.1 Disease Background 7
2.2 Risk Factors and Comorbidities 8
2.3 Global Trends 9
2.4 Forecast Methodology 9
2.4.1 Sources Used Tables 9
2.4.2 Forecast Assumptions and Methods 14
2.4.3 Sources Not Used 30
2.5 Epidemiological Forecast for Dyslipidemia (2015-2025) 31
2.5.1 Dyslipidemia 31
2.5.2 Familial Hypercholesterolemia 34
2.5.3 Increased Low-Density Lipoprotein Cholesterol 35
2.5.4 High Triglycerides 40
2.5.5 Very High Triglycerides 44
2.5.6 Low High-Density Lipoprotein Cholesterol 46
2.6 Discussion 50
2.6.1 Epidemiological Forecast Insight 50
2.6.2 Limitations of the Analysis 51
2.6.3 Strengths of the Analysis 52
3 Appendix 53
3.1 Bibliography 53
3.2 About the Authors 56
3.2.1 Epidemiologists 56
3.2.2 Reviewers 57
3.2.3 Global Director of Therapy Analysis and Epidemiology 58
3.3 About GlobalData 59
3.4 About EpiCast 59
3.5 Disclaimer 60

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Dyslipidemia 8
Table 2: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia 10
Table 3: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH 11
Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C 12
Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG 13
Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C 14
Table 7: 8MM, Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 32
Table 8: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 33
Table 9: 8MM, Total Prevalent Cases of Increased LDL-C, Ages ?20 Years, Both Sexes, N, Selected Years, 2015-2025 36
Table 10: 8MM, Total Prevalent Cases of High TG, Ages ?20 Years, Both Sexes, N, Selected Years, 2015-2025 41
Table 11: 8MM, Total Prevalent Cases of Very High TG, Ages ?20 Years, Both Sexes, N, Selected Years, 2015-2025 45
Table 12: 8MM, Total Prevalent Cases of Low HDL-C, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 46

1.2 List of Figures
Figure 1: 8MM Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, Both Sexes, N, 2015-2025 32
Figure 2: 8MM Diagnosed Prevalent Cases of Dyslipidemia, Ages ?20 Years, Both Sexes, N, 2015-2025 34
Figure 3: 8MM, Total Prevalent Cases of FH, Both Sexes, Ages ?20 Years, N, 2015 and 2025 35
Figure 4: 8MM, Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ?20 Years, N, 2015 and 2025 37
Figure 5: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ?20 Years, N, 2015 38
Figure 6: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ?20 Years, 2015 39
Figure 7: 8MM, Age-Standardized Total Prevalence of Increased LDL-C, Both Sexes, Ages ?20 Years, 2015 40
Figure 8: 8MM, Total Prevalent Cases of High TG, Both Sexes, Ages ?20 Years, N, 2015-2025 41
Figure 9: 8MM, Sex-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ?20 Years, N, 2015 42
Figure 10: 8MM, Age-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ?20 Years, 2015 43
Figure 11: 8MM, Age-Standardized Total Prevalence of High TG, Both Sexes, Ages ?20 Years, 2015 44
Figure 12: 8MM, Total Prevalent Cases of Very High TG, Both Sexes, Ages ?20 Years, N, 2015-2025 45
Figure 13: 8MM, Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ?20 Years, N, 2015-2025 47
Figure 14: 8MM, Sex-Specific Total Prevalent Cases of Low HDL-C, Ages ?20 Years, N, 2015 48
Figure 15: 8MM, Age-Specific Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ?20 Years, 2015 49
Figure 16: 8MM, Age-Standardized Total Prevalence of Low HDL-C, Both Sexes, Ages ?20 Years, 2015 50

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global cholesterol testing services market is expected to reach USD 17.5 billion by 2021 from USD 11.9 billion in 2016, growing at a CAGR of 8% during the forecast period. This market is segmented ...

Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dyslipidemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Dyslipidemia  - Epidemiology Forecast To 2023

Dyslipidemia  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Dyslipidemia  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Dyslipidemia  in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.